Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people...
DNA
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply...
Inovalon Expands Patient Data Connectivity Network by 110% Over 12 Months – Now Enabling Access to More Than 67% of U.S. Healthcare Providers
Expanded Access Further Eases Patient Data Exchange and Advances Industry InteroperabilityBOWIE, Md., April 04, 2023 (GLOBE NEWSWIRE) -- Inovalon, a...
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life...
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated...
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic...
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 31, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft...
Transplant Logistics Leader MediGO Issues Statement Welcoming HRSA Announcement on Organ Procurement and Transplantation Network Modernization Initiative
BALTIMORE, March 30, 2023 (GLOBE NEWSWIRE) -- MediGO, a Baltimore-based digital healthcare supply chain technology company focused on improving equity,...
Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of...
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX)...
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate...
IMUNON Reports 2022 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts...
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive...
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...